WallStSmart

Heron Therapeuti (HRTX)vsNovartis AG ADR (NVS)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 37845% more annual revenue ($57.36B vs $151.18M). NVS leads profitability with a 17.5% profit margin vs -22.5%. NVS earns a higher WallStSmart Score of 48/100 (D+).

HRTX

Avoid

29

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 5.0Quality: 4.5
Piotroski: 4/9Altman Z: -9.57

NVS

Hold

48

out of 100

Grade: D+

Growth: 4.0Profit: 9.0Value: 2.7Quality: 4.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for HRTX.

NVSSignificantly Overvalued (-67.6%)

Margin of Safety

-67.6%

Fair Value

$95.76

Current Price

$160.50

$64.74 premium

UndervaluedFair: $95.76Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HRTX0 strengths · Avg: 0/10

No standout strengths identified

NVS4 strengths · Avg: 9.3/10
Market CapQuality
$302.86B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
34.0%10/10

Strong operational efficiency at 34.0%

Return on EquityProfitability
26.9%9/10

Every $100 of equity generates 27 in profit

Free Cash FlowQuality
$4.76B8/10

Generating 4.8B in free cash flow

Areas to Watch

HRTX4 concerns · Avg: 3.8/10
Price/BookValuation
9.5x4/10

Trading at 9.5x book value

Revenue GrowthGrowth
1.3%4/10

1.3% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$56.69M3/10

Smaller company, higher risk/reward

NVS4 concerns · Avg: 4.0/10
P/E RatioValuation
30.6x4/10

Premium valuation, high expectations priced in

Price/BookValuation
8.1x4/10

Trading at 8.1x book value

Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Comparative Analysis Report

WallStSmart Research

Bull Case : HRTX

HRTX has a balanced fundamental profile.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Operating Margin, Return on Equity. Profitability is solid with margins at 17.5% and operating margin at 34.0%.

Bear Case : HRTX

The primary concerns for HRTX are Price/Book, Revenue Growth, EPS Growth. Debt-to-equity of 26.80 is elevated, increasing financial risk.

Bear Case : NVS

The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.

Key Dynamics to Monitor

HRTX profiles as a turnaround stock while NVS is a value play — different risk/reward profiles.

HRTX carries more volatility with a beta of 1.65 — expect wider price swings.

NVS is growing revenue faster at 4.7% — sustainability is the question.

NVS generates stronger free cash flow (4.8B), providing more financial flexibility.

Bottom Line

NVS scores higher overall (48/100 vs 29/100), backed by strong 17.5% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Heron Therapeuti

HEALTHCARE · BIOTECHNOLOGY · USA

Heron Therapeutics, Inc., a biotechnology company, is dedicated to developing treatments to address unmet medical needs. The company is headquartered in San Diego, California.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?